Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE 2.5/APAP 500 vs HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Oxycodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Management of moderate to moderately severe pain
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.
1-2 tablets (oxycodone 2.5-5 mg/APAP 500-1000 mg) orally every 4-6 hours as needed for pain; maximum APAP 4000 mg/day (consider lower APAP limit per institutional guidelines).
Oral: 1-2 tablets (5-10 mg hydrocodone/325-650 mg acetaminophen) every 4-6 hours as needed for pain; maximum daily doses: hydrocodone 40 mg, acetaminophen 3000 mg.
Oxycodone: 3.5-5.5 hours in healthy adults; steady state reached within 24 hours. Acetaminophen: 2-3 hours; prolonged in hepatic impairment.
Hydrocodone: 3.8-7.4 hours (terminal), prolonged in hepatic impairment. Acetaminophen: 1.5-2.5 hours (terminal).
e GFR 30-60 m L/min: no adjustment initially, monitor for adverse effects; e GFR <30 m L/min: reduce starting dose by 50% or extend dosing interval (e.g., every 6-8 hours); avoid in dialysis unless benefits outweigh risks.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use or reduce dose and frequency. Hemodialysis: Not recommended.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction; risk of hepatotoxicity from acetaminophen overdose.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS). High doses near term may cause neonatal respiratory depression.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence, neonatal withdrawal syndrome, and reduced fetal growth. Acetaminophen component: no known teratogenic risk at therapeutic doses.
Oxycodone/APAP is a fixed-dose combination; titration is limited by acetaminophen ceiling (max 4000 mg/day, lower in hepatic impairment or alcohol use). Use with caution in elderly, renal impairment, and respiratory compromise. Avoid in severe asthma or ileus. Prescribe the lowest effective dose for the shortest duration. Consider naloxone co-prescription if risk factors for opioid overdose. Not recommended for chronic pain without nonopioid alternatives.
Hydrocodone/acetaminophen carries a boxed warning for addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; and hepatotoxicity (acetaminophen). Avoid in patients with severe respiratory depression, acute or severe bronchial asthma, GI obstruction, or known acetaminophen hypersensitivity. Maximum acetaminophen dose from all sources should not exceed 4 g/day (3 g/day in at-risk patients). Use with caution in elderly, cachectic, or debilitated patients due to increased risk of respiratory depression. CYP3A4 inducers (e.g., rifampin) may reduce hydrocodone efficacy; CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. Do not combine with other CNS depressants without dose adjustment. Monitor for signs of opioid-induced constipation; prescribe a bowel regimen. Prescribe immediate-release formulations only for acute pain (generally ≤3 days). Avoid combining with MAOIs or within 14 days of MAOI use.
No interactions on record
No interactions on record
OXYCODONE 2.5/APAP 500 and HYDROCODONE BITARTRATE AND ACETAMINOPHEN are distinct pharmacological agents. OXYCODONE 2.5/APAP 500 belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain. HYDROCODONE BITARTRATE AND ACETAMINOPHEN belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OXYCODONE 2.5/APAP 500 carries a safety status of Category D/X, whereas HYDROCODONE BITARTRATE AND ACETAMINOPHEN safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Oxycodone is metabolized primarily by CYP3A4 and CYP2D6 to noroxycodone, oxymorphone, and glucuronides. Acetaminophen is metabolized via glucuronidation, sulfation, and CYP2E1-mediated oxidation to N-acetyl-p-benzoquinone imine (NAPQI).
Hydrocodone: primarily CYP3A4 and CYP2D6 to hydromorphone (active). Acetaminophen: primarily glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation to NAPQI (toxic).
Oxycodone: primarily renal (87% as metabolites, 10% unchanged). Acetaminophen: primarily renal (90-100% as glucuronide and sulfate conjugates, 2-5% unchanged). Fecal elimination <10%
Renal excretion of metabolites (hydrocodone: ~60% as conjugates, <12% unchanged; acetaminophen: ~85-90% as glucuronide and sulfate conjugates, <5% unchanged). Biliary/fecal elimination of minor metabolites.
Oxycodone: 38-45% (primarily albumin). Acetaminophen: 10-20% (albumin).
Hydrocodone: ~20-50% bound to albumin and other proteins. Acetaminophen: 10-25% bound to albumin.
Oxycodone: 2-3 L/kg (large Vd indicates extensive tissue distribution). Acetaminophen: 0.9-1.0 L/kg (distributes uniformly throughout body water).
Hydrocodone: 3.3-4.7 L/kg (extensive tissue distribution). Acetaminophen: 0.75-1.0 L/kg (primarily total body water).
Oxycodone: oral 60-87% (first-pass metabolism). Acetaminophen: oral 70-90% (minimal first-pass). Rectal: variable for both.
Oral: Hydrocodone ~70-80% (first-pass metabolism). Acetaminophen ~60-90% (product dependent).
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose by 50% and monitor; Child-Pugh C: avoid use due to risk of APAP toxicity and opioid accumulation.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce total daily dose by 50% or extend dosing interval. Child-Pugh C: Avoid use.
Weight-based: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg/dose) orally every 4-6 hours as needed; APAP component: 10-15 mg/kg/dose (max 500 mg/dose) every 4-6 hours, not to exceed 5 doses (75 mg/kg/day) in 24 hours. Not recommended for children < 2 years.
Not recommended for children <18 years due to safety concerns. For postoperative tonsillectomy/adenoidectomy: contraindicated.
Start at lowest effective dose (e.g., 0.5-1 tablet) every 4-6 hours; increase cautiously; avoid APAP doses >3000 mg/day; monitor for sedation, constipation, and respiratory depression; consider alternative if renal or hepatic impairment.
Initiate at lowest effective dose (e.g., 2.5 mg hydrocodone/325 mg acetaminophen) and titrate slowly; monitor for CNS depression and constipation. Avoid in renal impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen overdose.
Respiratory depression, hepatic injury, adrenal insufficiency, hypotension, seizures, severe hypotension, GI obstruction, use in elderly and debilitated patients, renal impairment, drug dependence.
Respiratory depression, drug dependence, abuse potential, risks with CNS depressants, elderly/debilitated patients, hepatic impairment, renal impairment, severe hypotension, head injury, seizures, use in pregnancy, use in breastfeeding, adrenal insufficiency, anaphylaxis, withdrawal, and driving impairment.
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; acetaminophen poisoning.
Significant respiratory depression, acute or severe bronchial asthma, GI obstruction (including paralytic ileus), hypersensitivity to hydrocodone or acetaminophen, severe hepatic impairment, and known or suspected gastrointestinal obstruction.
Avoid alcohol entirely. High-fat meals may delay absorption, but no specific food restrictions. Maintain adequate fluid and fiber intake to prevent constipation.
Avoid alcohol consumption due to increased risk of hepatotoxicity and additive CNS depression. Grapefruit juice may inhibit CYP3A4 and potentially increase hydrocodone levels; consider avoiding or limiting intake. No significant food restrictions otherwise; may take with or without food. Maintain adequate hydration to prevent constipation.
Oxycodone excreted into breast milk; M/P ratio approximately 3.4:1. Acetaminophen M/P ratio ~0.91. American Academy of Pediatrics recommends caution; monitor infant for sedation and respiratory depression. Maximum daily oxycodone dose in milk ~7% of maternal weight-adjusted dose.
Hydrocodone is excreted into human breast milk, with an M/P ratio approximately 2.5. Postpartum use may lead to infant sedation and respiratory depression, especially in CYP2D6 ultra-rapid metabolizers. Acetaminophen is excreted in low levels. Use is generally avoided due to risks; if used, monitor infant for drowsiness and feeding difficulties.
Pregnancy increases clearance of oxycodone by up to 60% due to enhanced hepatic metabolism; consider dose adjustments based on pain control. Acetaminophen pharmacokinetics minimally altered; no dose adjustment typically needed. Monitor for need to increase oxycodone dose in second and third trimesters.
No dosing adjustment recommended specifically for pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may result in lower serum concentrations; however, due to fetal risks, use the lowest effective dose for the shortest duration. Avoid use in third trimester unless necessary; monitor for neonatal withdrawal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or break tablets; swallow whole.,Avoid alcohol and other sedatives (benzodiazepines, muscle relaxants) as they increase risk of severe drowsiness, respiratory depression, and death.,Do not drive or operate machinery until you know how this medication affects you.,Keep out of reach of children and pets; dispose of unused medication via drug take-back programs.,Report any signs of allergic reaction (rash, difficulty breathing), severe constipation, nausea/vomiting, or confusion.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Inform all healthcare providers that you are taking this medication.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and any products containing acetaminophen (e.g., Tylenol, cold medicines) to prevent liver damage.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store in a secure place away from children and pets; dispose of unused medication via a drug take-back program.,Contact your doctor immediately if you experience shallow breathing, difficulty waking, confusion, or signs of allergic reaction.,Do not stop abruptly; withdrawal symptoms include anxiety, sweating, diarrhea, and muscle aches.,Inform all healthcare providers that you are taking this medication.,Use exactly as directed; misuse can lead to addiction, overdose, or death.